{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:46:59Z","timestamp":1782928019657,"version":"3.54.5"},"reference-count":13,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/eurheartj\/ehag478","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:48:01Z","timestamp":1780573681000},"source":"Crossref","is-referenced-by-count":0,"title":["Vascular Ehlers\u2013Danlos syndrome: should we treat asymptomatic patients?"],"prefix":"10.1093","author":[{"given":"Michael","family":"Frank","sequence":"first","affiliation":[{"name":"AP-HP, Service de M\u00e9decine Vasculaire et Centre de R\u00e9f\u00e9rence des Maladies Art\u00e9rielles Rares, H\u00f4pital Europ\u00e9en Georges-Pompidou , Paris F-75015 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-3569","authenticated-orcid":false,"given":"Pierre","family":"Boutouyrie","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, PARCC , Paris F-75015 ,","place":["France"]},{"name":"AP-HP, Service de Pharmacologie, H\u00f4pital Europ\u00e9en Georges-Pompidou , Paris F-75015 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-381X","authenticated-orcid":false,"given":"Xavier","family":"Jeunemaitre","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, PARCC , Paris F-75015 ,","place":["France"]},{"name":"AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou, Service de M\u00e9decine G\u00e9nomique des Maladies Rares , 40 rue Leblanc, Paris F-75015 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026070113025206200_ehag478-B1","volume-title":"GeneReviews\u00ae","author":"Byers","year":"1993-2026"},{"key":"2026070113025206200_ehag478-B2","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/j.jacc.2019.01.058","article-title":"Vascular Ehlers-Danlos syndrome: long-term observational study","volume":"73","author":"Frank","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026070113025206200_ehag478-B3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1161\/CIRCULATIONAHA.124.072849","article-title":"Efficacy of irbesartan in celiprolol-treated patients with vascular Ehlers-Danlos syndrome","volume":"151","author":"Jeunemaitre","year":"2025","journal-title":"Circulation"},{"key":"2026070113025206200_ehag478-B4","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1161\/CIR.0000000000001106","article-title":"2022 ACC\/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"146","author":"Isselbacher","year":"2022","journal-title":"Circulation"},{"key":"2026070113025206200_ehag478-B5","doi-asserted-by":"publisher","first-page":"e003864","DOI":"10.1161\/CIRCGEN.122.003864","article-title":"Features of vascular Ehlers-Danlos syndrome among biobank participants harboring predicted high-risk COL3A1 genotypes","volume":"16","author":"Lui","year":"2023","journal-title":"Circ Genom Precis Med"},{"key":"2026070113025206200_ehag478-B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11906-020-01077-7","article-title":"The story of the silent killer: a history of hypertension: its discovery, diagnosis, treatment, and debates","volume":"22","author":"Kalehoff","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"2026070113025206200_ehag478-B7","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular diseases and risks collaborators. Global burden of cardiovascular diseases and risks, 1990\u20132022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026070113025206200_ehag478-B8","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1161\/01.CIR.0000121741.50315.C2","article-title":"Increased carotid wall stress in vascular Ehlers-Danlos syndrome","volume":"109","author":"Boutouyrie","year":"2004","journal-title":"Circulation"},{"key":"2026070113025206200_ehag478-B9","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/S0140-6736(10)60960-9","article-title":"Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial","volume":"376","author":"Ong","year":"2010","journal-title":"Lancet"},{"key":"2026070113025206200_ehag478-B10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ejvs.2020.10.020","article-title":"Celiprolol treatment in patients with vascular Ehlers-Danlos syndrome","volume":"61","author":"Baderkhan","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026070113025206200_ehag478-B11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/j.1552-4604.1986.tb02899.x","article-title":"Effect of celiprolol, a new beta 1-alpha 2 blocker, on the cardiovascular response to exercise","volume":"26","author":"Caruso","year":"1986","journal-title":"J Clin Pharmacol"},{"key":"2026070113025206200_ehag478-B12","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1093\/eurheartj\/ehae526","article-title":"Management of aortic disease in children with FBN1-related Marfan syndrome","volume":"45","author":"Mui\u00f1o-Mosquera","year":"2024","journal-title":"Eur Heart J"},{"key":"2026070113025206200_ehag478-B13","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.3390\/jcm13144255","article-title":"Current evidence and future perspectives in the medical management of vascular Ehlers-Danlos syndrome: focus on vascular prevention","volume":"13","author":"Buso","year":"2024","journal-title":"J Clin Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag478\/68666295\/ehag478.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag478\/68666295\/ehag478.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:03:28Z","timestamp":1782925408000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag478\/8723084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":13,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag478","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"ehag478"}}